LMR Partners’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

LMR Partners’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$1.01M	–	1281
2022 Q4	$1.01M	Hold	100,000	–	–	0.02%	716
2022 Q3	$992K	Hold	100,000	–	–	0.02%	738
2022 Q2	$990K	Hold	100,000	–	–	0.02%	750
2022 Q1	$986K	Hold	100,000	–	–	0.01%	812
2021 Q4	$984K	Hold	100,000	–	–	0.01%	716
2021 Q3	$974K	Hold	100,000	–	–	0.01%	654
2021 Q2	$967K	Buy	+100,000	New	+$972K	0.01%	553

LMR Partners's BIOT Position: Q1 2023 in Review

LMR Partners sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 100,000 shares — an estimated $1.01M sold.

LMR Partners first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $1.01M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

LMR Partners reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
LMR Partners sold 100,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.01M.
LMR Partners first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
LMR Partners's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.01M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.